|Bid||82.98 x 1100|
|Ask||82.98 x 800|
|Day's Range||82.35 - 84.95|
|52 Week Range||71.59 - 92.57|
|Beta (5Y Monthly)||0.55|
|PE Ratio (TTM)||19.76|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||110.83|
The following statement is being issued by Levi & Korsinsky, LLP:
SAN DIEGO, CA / ACCESSWIRE / December 6, 2021 / Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) securities between January 13, 2020 and September 3, 2021, for violations of the Securities Exchange Act of 1934.
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021, inclusive (the "Class Period"), of the important December 22, 2021 lead plaintiff deadline.